CMS Announces Plans to Cover Alzheimer’s Treatment Drug and the PET/CT Scans Needed to Begin treating Patients With This Drug
September 1, 2023
New England PET is fully prepared to perform these crucial Beta Amyloid PET/CT Scans at all five of our locations!
![September 19, 2023](https://assets-global.website-files.com/6509f84a08a882d57aaba174/650a0623cf0ecc2eeab93736_news-cms-announces-plans-feature.jpg)
On July 6, 2023 CMS announced that it would cover the Alzheimer’s Treatment drug Lequembi and, as part of this decision, required the treating physician to submit proof of a positive Beta Amyloid PET/CT scan prior to starting any treatment.
Then, on July 20, 2023 CMS published a Proposed Decision Memo indicating that it would cover the Beta Amyloid PET/CT scan required before starting treatment with any FDA approved Alzheimer’s Treatment drug.
New England PET is fully prepared to perform these crucial Beta Amyloid PET/CT Scans at all five of our locations!